Pharmacologic treatment of anorexia nervosa: Where do we go from here?

Anorexia nervosa (AN) is a serious mental disorder, characterized by severely low weight and cognitive distortions about body shape and weight. AN is generally associated with a range of psychological symptoms, including depression, anxiety, obsessions, and rituals. The current study summarized find...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The International journal of eating disorders 2005, Vol.37 (S1), p.S60-S63
Hauptverfasser: Attia, Evelyn, Schroeder, Laura
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S63
container_issue S1
container_start_page S60
container_title The International journal of eating disorders
container_volume 37
creator Attia, Evelyn
Schroeder, Laura
description Anorexia nervosa (AN) is a serious mental disorder, characterized by severely low weight and cognitive distortions about body shape and weight. AN is generally associated with a range of psychological symptoms, including depression, anxiety, obsessions, and rituals. The current study summarized findings from randomized controlled trials (RCT) using pharmacologic treatments in patients with AN. We conducted a review of literature using Medline. Several classes of pharmacologic agents have been studied in small samples of patients with acute AN without finding clear benefit to eating, weight, body shape concerns, or associated psychopathology. Studies have been limited by small sample sizes, as well as by research design with most studies adding medication to comprehensive hospital‐based treatment programs. Future directions for pharmacologic treatment research in AN should include outpatient trials, rigorous study of atypical antipsychotic medication, and assessment of medication effect for relapse prevention in weight‐restored patients. © 2005 by Wiley Periodicals, Inc.
doi_str_mv 10.1002/eat.20133
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67809949</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67809949</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4523-dd1e7f37c25ebbac32cb2b13630d0cc4c2b3b347c1a54a71b41f932f344e40fd3</originalsourceid><addsrcrecordid>eNqFkMlOwzAQhi0EglI48ALIJyQOab1l44Iq1AWprCoqN8txJhBIYrBTKG9PSgqcEKeRRt98M_MjdEBJjxLC-qDqHiOU8w3UoSSOPEqi-03UISwMPC7CaAftOvdECAk48bfRDvUjn3HGOmh0_ahsqbQpzEOucW0bVwlVjU2GVWUsLHOFK7BvxqkTPH8ECzg1-B3wg8GZNSVetU730FamCgf769pFd6Ph7GziTa_G52eDqadFs9BLUwphxkPNfEgSpTnTCUsob85KidZCs4QnzcGaKl-okCaCZjFnGRcCBMlS3kVHrffFmtcFuFqWudNQFKoCs3AyCCMSxyL-F2QkDDhnK_C4BbU1zlnI5IvNS2U_JCVyla5sEpFf6Tbs4Vq6SEpIf8l1nA3Qb4H3vICPv01yOJh9K712Inc1LH8mlH1ufuGhL-eXYxnc31yIyexWzvgngXuSRg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20763329</pqid></control><display><type>article</type><title>Pharmacologic treatment of anorexia nervosa: Where do we go from here?</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Attia, Evelyn ; Schroeder, Laura</creator><creatorcontrib>Attia, Evelyn ; Schroeder, Laura</creatorcontrib><description>Anorexia nervosa (AN) is a serious mental disorder, characterized by severely low weight and cognitive distortions about body shape and weight. AN is generally associated with a range of psychological symptoms, including depression, anxiety, obsessions, and rituals. The current study summarized findings from randomized controlled trials (RCT) using pharmacologic treatments in patients with AN. We conducted a review of literature using Medline. Several classes of pharmacologic agents have been studied in small samples of patients with acute AN without finding clear benefit to eating, weight, body shape concerns, or associated psychopathology. Studies have been limited by small sample sizes, as well as by research design with most studies adding medication to comprehensive hospital‐based treatment programs. Future directions for pharmacologic treatment research in AN should include outpatient trials, rigorous study of atypical antipsychotic medication, and assessment of medication effect for relapse prevention in weight‐restored patients. © 2005 by Wiley Periodicals, Inc.</description><identifier>ISSN: 0276-3478</identifier><identifier>EISSN: 1098-108X</identifier><identifier>DOI: 10.1002/eat.20133</identifier><identifier>PMID: 15852322</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>anorexia nervosa ; Anorexia Nervosa - drug therapy ; Antidepressive Agents - therapeutic use ; Antipsychotic Agents - therapeutic use ; eating disorders ; Gastrointestinal Agents - therapeutic use ; Humans ; medication ; Narcotic Antagonists - therapeutic use ; pharmacology ; review</subject><ispartof>The International journal of eating disorders, 2005, Vol.37 (S1), p.S60-S63</ispartof><rights>Copyright © 2005 Wiley Periodicals, Inc.</rights><rights>2005 by Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4523-dd1e7f37c25ebbac32cb2b13630d0cc4c2b3b347c1a54a71b41f932f344e40fd3</citedby><cites>FETCH-LOGICAL-c4523-dd1e7f37c25ebbac32cb2b13630d0cc4c2b3b347c1a54a71b41f932f344e40fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Feat.20133$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Feat.20133$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,4010,27902,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15852322$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Attia, Evelyn</creatorcontrib><creatorcontrib>Schroeder, Laura</creatorcontrib><title>Pharmacologic treatment of anorexia nervosa: Where do we go from here?</title><title>The International journal of eating disorders</title><addtitle>Int. J. Eat. Disord</addtitle><description>Anorexia nervosa (AN) is a serious mental disorder, characterized by severely low weight and cognitive distortions about body shape and weight. AN is generally associated with a range of psychological symptoms, including depression, anxiety, obsessions, and rituals. The current study summarized findings from randomized controlled trials (RCT) using pharmacologic treatments in patients with AN. We conducted a review of literature using Medline. Several classes of pharmacologic agents have been studied in small samples of patients with acute AN without finding clear benefit to eating, weight, body shape concerns, or associated psychopathology. Studies have been limited by small sample sizes, as well as by research design with most studies adding medication to comprehensive hospital‐based treatment programs. Future directions for pharmacologic treatment research in AN should include outpatient trials, rigorous study of atypical antipsychotic medication, and assessment of medication effect for relapse prevention in weight‐restored patients. © 2005 by Wiley Periodicals, Inc.</description><subject>anorexia nervosa</subject><subject>Anorexia Nervosa - drug therapy</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>eating disorders</subject><subject>Gastrointestinal Agents - therapeutic use</subject><subject>Humans</subject><subject>medication</subject><subject>Narcotic Antagonists - therapeutic use</subject><subject>pharmacology</subject><subject>review</subject><issn>0276-3478</issn><issn>1098-108X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMlOwzAQhi0EglI48ALIJyQOab1l44Iq1AWprCoqN8txJhBIYrBTKG9PSgqcEKeRRt98M_MjdEBJjxLC-qDqHiOU8w3UoSSOPEqi-03UISwMPC7CaAftOvdECAk48bfRDvUjn3HGOmh0_ahsqbQpzEOucW0bVwlVjU2GVWUsLHOFK7BvxqkTPH8ECzg1-B3wg8GZNSVetU730FamCgf769pFd6Ph7GziTa_G52eDqadFs9BLUwphxkPNfEgSpTnTCUsob85KidZCs4QnzcGaKl-okCaCZjFnGRcCBMlS3kVHrffFmtcFuFqWudNQFKoCs3AyCCMSxyL-F2QkDDhnK_C4BbU1zlnI5IvNS2U_JCVyla5sEpFf6Tbs4Vq6SEpIf8l1nA3Qb4H3vICPv01yOJh9K712Inc1LH8mlH1ufuGhL-eXYxnc31yIyexWzvgngXuSRg</recordid><startdate>2005</startdate><enddate>2005</enddate><creator>Attia, Evelyn</creator><creator>Schroeder, Laura</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>2005</creationdate><title>Pharmacologic treatment of anorexia nervosa: Where do we go from here?</title><author>Attia, Evelyn ; Schroeder, Laura</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4523-dd1e7f37c25ebbac32cb2b13630d0cc4c2b3b347c1a54a71b41f932f344e40fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>anorexia nervosa</topic><topic>Anorexia Nervosa - drug therapy</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>eating disorders</topic><topic>Gastrointestinal Agents - therapeutic use</topic><topic>Humans</topic><topic>medication</topic><topic>Narcotic Antagonists - therapeutic use</topic><topic>pharmacology</topic><topic>review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Attia, Evelyn</creatorcontrib><creatorcontrib>Schroeder, Laura</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The International journal of eating disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Attia, Evelyn</au><au>Schroeder, Laura</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacologic treatment of anorexia nervosa: Where do we go from here?</atitle><jtitle>The International journal of eating disorders</jtitle><addtitle>Int. J. Eat. Disord</addtitle><date>2005</date><risdate>2005</risdate><volume>37</volume><issue>S1</issue><spage>S60</spage><epage>S63</epage><pages>S60-S63</pages><issn>0276-3478</issn><eissn>1098-108X</eissn><abstract>Anorexia nervosa (AN) is a serious mental disorder, characterized by severely low weight and cognitive distortions about body shape and weight. AN is generally associated with a range of psychological symptoms, including depression, anxiety, obsessions, and rituals. The current study summarized findings from randomized controlled trials (RCT) using pharmacologic treatments in patients with AN. We conducted a review of literature using Medline. Several classes of pharmacologic agents have been studied in small samples of patients with acute AN without finding clear benefit to eating, weight, body shape concerns, or associated psychopathology. Studies have been limited by small sample sizes, as well as by research design with most studies adding medication to comprehensive hospital‐based treatment programs. Future directions for pharmacologic treatment research in AN should include outpatient trials, rigorous study of atypical antipsychotic medication, and assessment of medication effect for relapse prevention in weight‐restored patients. © 2005 by Wiley Periodicals, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>15852322</pmid><doi>10.1002/eat.20133</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0276-3478
ispartof The International journal of eating disorders, 2005, Vol.37 (S1), p.S60-S63
issn 0276-3478
1098-108X
language eng
recordid cdi_proquest_miscellaneous_67809949
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects anorexia nervosa
Anorexia Nervosa - drug therapy
Antidepressive Agents - therapeutic use
Antipsychotic Agents - therapeutic use
eating disorders
Gastrointestinal Agents - therapeutic use
Humans
medication
Narcotic Antagonists - therapeutic use
pharmacology
review
title Pharmacologic treatment of anorexia nervosa: Where do we go from here?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T19%3A24%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacologic%20treatment%20of%20anorexia%20nervosa:%20Where%20do%20we%20go%20from%20here?&rft.jtitle=The%20International%20journal%20of%20eating%20disorders&rft.au=Attia,%20Evelyn&rft.date=2005&rft.volume=37&rft.issue=S1&rft.spage=S60&rft.epage=S63&rft.pages=S60-S63&rft.issn=0276-3478&rft.eissn=1098-108X&rft_id=info:doi/10.1002/eat.20133&rft_dat=%3Cproquest_cross%3E67809949%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20763329&rft_id=info:pmid/15852322&rfr_iscdi=true